Positive topline results from the DESTINY-Lung04 phase 3 trial showed Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard… read more.
Menstrual leave and flexible work arrangements are the forms of support women with endometriosis say would help them most, according to a new study by researchers at Semmelweis University published… read more.
Johnson & Johnson announced U.S. 510(k) regulatory clearance for MONARCH QUEST 3, the latest software update for the MONARCH Platform. The update reflects the company’s continued commitment to… read more.
A new study published in Diabetes Care finds that bone loss alone does not explain the increased fracture risk observed in some older adults with type 2 diabetes. The article, “Type… read more.
A new study of sunscreens, baby lotions, shampoos, soaps, and other everyday products found that nearly all contained chemicals not disclosed on their labels. Most contained at least one unlabeled… read more.
Lantheus Holdings, Inc. announced FDA approval of TAUKLARIFY (florquinitau F 18 injection), also referred to as MK 6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of… read more.
Older adults with cardiovascular disease (CVD) often have coexisting cognitive impairment and frailty, conditions that can significantly affect treatment decisions, recovery, independence and quality of life and should… read more.
Emergency Medicine & Intensive Care
Nearly 500 children have been injured by e-scooters since 2019, with less than 2% reportedly wearing a helmet, and their average age just 12, shows a 3-centre study… read more.
Genmab and AbbVie provided clarification on the primary endpoints from the Phase 3 EPCORE DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared… read more.
A study examined the brains of children at increased risk of developing schizophrenia to determine whether signs of vulnerability can be detected during childhood. The findings suggest that… read more.
Around one in six people experience infertility, with irregular or absent ovulation among the most common causes. The drug clomiphene citrate has long been a mainstay of fertility treatment, but… read more.
ALK announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX) and house dust mite tablet (ACARIZAX) for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
